Cytologic diagnosis | Origin/site/type | Number of cases | Total number |
---|---|---|---|
Metastatic adenocarcinoma | 317 (50.8%) | ||
GI tract | 143 (45.1%) | ||
Pancreatobiliary | 74 (23.3%) | ||
Breast | 44 (13.9%) | ||
Lung | 24 (7.6%) | ||
GYN tract | 12 (3.8%) | ||
Kidney | 12 (3.8%) | ||
Prostate | 5 (1.6%) | ||
Thyroid | 1 (0.3%) | ||
Adrenal | 2 (0.6%) | ||
Hepatocellular carcinomaa | 97 (15.5%) | ||
Cholangiocarcinomaa | 73 (11.7%) | ||
Neuroendocrine neoplasm | 58 (9.3%) | ||
Well-differentiated NETs | 16 (27.6%) | ||
Poorly-differentiated NECs | 42 (72.4%) | ||
Squamous cell Carcinoma | 24 (3.8%) | ||
Lymphoma | 17 (2.7%) | ||
DLBCL | 11 (64.7%) | ||
Hodgkin lymphoma | 3 (17.6%) | ||
SLL/CLL | 1 (5.9%) | ||
Follicular lymphoma | 1 (5.9%) | ||
Multiple myeloma | 1 (5.9%) | ||
Sarcoma | 11 (1.8%) | ||
Leiomyosarcoma | 3 (27.2%) | ||
EBV-associated leiomyosarcomaa | 1 (9.1%) | ||
Undifferentiated pleomorphic sarcoma | 2 (18.2%) | ||
Embryonal sarcomaa | 1 (9.1%) | ||
Malignant SFT | 1 (9.1%) | ||
Myxoid liposarcoma | 1 (9.1%) | ||
GIST | 2 (18.2%) | ||
Melanoma | 4 (0.6%) | ||
Combined HCC-CCa | 3 (0.5%) | ||
Urothelial carcinoma | 3 (0.5%) | ||
Thymic carcinoma | 2 (0.3%) | ||
Hepatoblastomaa | 1 (0.2%) | ||
Paragnaglioma | 1 (0.2%) | ||
Mesothelioma | 1 (0.2%) | ||
CUP | 12 (1.9%) | ||
Total | 624 (100%) |